FTC and FDA Healthcare Advertising: Who Regulates Which Claim?

“FDA compliant” and “FTC approved” are common phrases in healthcare marketing reviews. They often reveal that the review began with the wrong question.

The FTC and FDA share a concern with misleading health promotion, but they do not regulate every advertiser, product, service, and medium in the same way. Before assessing an ad, identify who is speaking, what is being promoted, which product or service is involved, who the audience is, what the express and implied claims are, and where the message will run.

This article reflects federal sources reviewed on September 6, 2026. It is general information, not legal advice. Statutes, regulations, product status, state law, professional rules, and enforcement positions require current, fact-specific review. Qualified FDA/FTC and healthcare counsel should approve high-risk campaigns before publication.

The FTC asks what the ad communicates and whether it is supported

The FTC Act prohibits deceptive and unfair acts or practices. In advertising, the Commission evaluates the overall or net impression, not just technically true sentences. Images, omissions, headlines, testimonials, disclosures, and page sequence can all contribute to a claim.

FTC staff’s Health Products Compliance Guidance explains that health-related benefit and safety claims generally require competent and reliable scientific evidence. The appropriate support depends on the claim, but marketers should not stretch a study beyond its product, dose, population, comparator, duration, or measured outcome.

Evidence must exist before dissemination. A clinician’s belief, patient story, manufacturer sales sheet, conference abstract, or statement that a product is “FDA cleared” does not automatically support the practice’s broader efficacy or superiority claim.

FDA scope depends on the product and speaker

FDA regulates labeling for drugs and devices and advertising for prescription drugs and restricted devices under specified authorities. FDA’s Office of Prescription Drug Promotion reviews prescription-drug advertising and promotional labeling made by or on behalf of manufacturers, packers, or distributors. Its Bad Ad materials emphasize truthful, balanced communication, material facts, supported claims, and risk information.

That is more precise than saying “FDA governs treatment claims.” An independent medical practice marketing its professional services is not automatically subject to the same prescription-drug advertising requirements as a manufacturer’s branded campaign. A manufacturer-funded provider post, a compounded-drug campaign, a device promotion, and a service page may each receive a different analysis.

FDA also notes that OPDP does not regulate advertising for several categories, including over-the-counter drugs and medical devices generally; other FDA centers, FTC authority, and specific rules may apply. Do not infer “unregulated.”

Off-label care and promotion are not the same question

Clinicians may use approved products off label when medically appropriate within the practice of medicine. Manufacturer promotion of unapproved uses is a different, highly regulated area. Provider advertising that names or promotes an off-label use can still raise complex issues involving speaker status, manufacturer relationships, claim substantiation, misbranding theories, state law, and professional conduct.

The old shortcut—“off-label use is legal, but advertising it is always prohibited”—is too broad for an article aimed at every practice. The responsible answer is to obtain counsel familiar with the specific product and arrangement before promotion.

Do not use “off label” as a provocative marketing hook. It may cause patients to infer novelty, superiority, or endorsement that the evidence does not support.

Testimonials and images can make the strongest claim

The FTC holds advertisers responsible for claims conveyed through endorsements. A patient can honestly report a result, but that experience does not prove the treatment will work for others. If a testimonial conveys a specific outcome as generally expected, the advertiser needs adequate support or a clear, conspicuous disclosure of generally expected performance in the depicted circumstances. That substantiation review belongs alongside—not inside—the separate patient testimonial permission process.

“Results may vary” usually does not change the net impression. Nor does a disclaimer repair a dominant image that communicates more than the evidence supports.

Material connections—including payment, free or discounted treatment, employment, gifts, or other benefits—must be disclosed when they could affect how the endorsement is weighed. Privacy authorization and advertising substantiation remain separate requirements, including when a creator’s post passes through the practice’s social media approval system.

A worked review: a compounded medication campaign

Consider a practice ad that says, “The next generation of weight loss—clinically proven and personalized,” beside a branded image of a compounded medication and an exceptional testimonial.

The review should identify the exact drug or ingredients, approval and compounding status, who supplied or funded the creative, whether a regulated manufacturer or distributor is involved, and which federal and state rules apply. It should inventory “next generation,” “clinically proven,” “personalized,” the depicted weight change, and any implied safety or comparative claims.

Counsel and clinical reviewers then examine the evidence, product-specific restrictions, risk communication, testimonial typicality, material connections, pharmacy and telehealth requirements, privacy authorization, and platform policy. If “clinically proven” relies on evidence for a different approved product or formulation, the claim may overreach.

The solution is not to add “results may vary” in small type. It is to narrow or remove every claim the actual evidence and regulatory status do not support.

“FDA approved” needs a complete object

FDA may approve a drug for specified indications or approve a device through a particular pathway; many devices are cleared rather than approved. A practice, technique, provider, facility, or off-label use does not become “FDA approved” because it uses an FDA-approved component.

State exactly what the agency action covered and do not imply broader endorsement. Confirm the current labeling, indication, population, and status at publication. Product status can change, and copied manufacturer language can become stale.

Build a claim file, not a disclaimer file

Before publication, preserve:

• the final ad, landing page, audience, and medium;
• the identity and regulatory role of every speaker, sponsor, product, and service;
• express and implied claims, including visuals and omissions;
• evidence mapped to each claim and its limitations;
• benefit, risk, typicality, and material-connection disclosures;
• privacy, state, professional, and platform review; and
• named clinical and legal approval with an expiration or re-review trigger.

Disclosures must be clear and conspicuous and cannot contradict the headline claim. If an accurate disclosure makes the offer sound materially different, the original claim was probably too broad.

Precision is the creative advantage

Healthcare advertising does not become credible by piling agency acronyms into the footer. It becomes credible when the advertiser can say exactly what is known, what is not, and why the evidence fits the claim. That precision is also what allows a premium healthcare brand to signal quality without relying on inflated promises.

Start with jurisdiction. Then map claim to evidence. The result may sound less dramatic, but it gives patients information they can actually use—and gives the practice an ad it can defend.

Primary sources

• FTC: Health Products Compliance Guidance
• FTC: Endorsement Guides Q&A
• FDA: Office of Prescription Drug Promotion
• FDA: Bad Ad Program and prescription-drug promotion issues
• FDA: Laws and regulations for advertising and promotional labeling